Roche/Ventana
This article was originally published in The Gray Sheet
Executive Summary
Roche continues pursuit of diagnostic firm Ventana Medical systems, extending its $75-per-share offer to acquire the company until Aug. 23. The drug and diagnostic giant initiated a hostile takeover of Ventana in June, originally extending the offer, equal to about $3 billion in total, through July 26. Ventana's board says the bid - a 44% premium over Ventana's June 22 stock price - is "wholly inadequate." Since the original offer, Ventana's shares have shot up about 60%, closing at $83.02 on July 27. The deal would give Roche entry into the $1 billion tissue-based testing market and provide diagnostic platforms to pair with its targeted cancer drugs (1"The Gray Sheet" July 2, 2007, p. 10)...
You may also be interested in...
Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.